Industry News (Jul 2023 to Dec 2023)

Abstract

This article provides an insightful overview of recent advancements and significant events in organoid research and technology. It covers the transition of HUB Organoids to a private company, the inaugural meeting of the International Society of Organoid Research in Singapore, and developments in organoid group standards at Tsinghua Changgeng Hospital. Additionally, it highlights breakthroughs in automated culture technology, major acquisitions such as Roche's purchase of Herophilus, and substantial funding rounds like Seraxis's $50 million for diabetes organoid therapy, demonstrating the dynamic growth and potential of this field.